These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 28844164)

  • 1. Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis.
    Thomas K; Proschmann U; Ziemssen T
    Expert Opin Pharmacother; 2017 Oct; 18(15):1649-1660. PubMed ID: 28844164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.
    Scott LJ
    CNS Drugs; 2011 Aug; 25(8):673-98. PubMed ID: 21790210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS).
    Meissner A; Limmroth V
    Mult Scler Relat Disord; 2016 Jul; 8():19-26. PubMed ID: 27456870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.
    Guarnera C; Bramanti P; Mazzon E
    Drug Des Devel Ther; 2017; 11():2193-2207. PubMed ID: 28814828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis.
    Tanasescu R; Constantinescu CS
    Expert Opin Drug Metab Toxicol; 2014 Apr; 10(4):621-30. PubMed ID: 24579791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis.
    Izquierdo G; O'Connor P; Montalban X; von Rosenstiel P; Cremer M; de Vera A; Sfikas N; Francis G; Radue EW; Kappos L
    Mult Scler; 2014 Jun; 20(7):877-81. PubMed ID: 24293455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fingolimod: a review of its mode of action in the context of its efficacy and safety profile in relapsing forms of multiple sclerosis.
    Jeffery DR; Rammohan KW; Hawker K; Fox E
    Expert Rev Neurother; 2016; 16(1):31-44. PubMed ID: 26587577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical discovery and development of fingolimod for the treatment of multiple sclerosis.
    Volpi C; Orabona C; Macchiarulo A; Bianchi R; Puccetti P; Grohmann U
    Expert Opin Drug Discov; 2019 Nov; 14(11):1199-1212. PubMed ID: 31389262
    [No Abstract]   [Full Text] [Related]  

  • 9. Benefit-Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis.
    Comi G; Hartung HP; Bakshi R; Williams IM; Wiendl H
    Drugs; 2017 Oct; 77(16):1755-1768. PubMed ID: 28905255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis.
    Ward MD; Jones DE; Goldman MD
    Mult Scler Relat Disord; 2016 Sep; 9():47-9. PubMed ID: 27645342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis.
    Vasiliou S
    Drugs Today (Barc); 2010 May; 46(5):315-25. PubMed ID: 20517533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy.
    Laroni A; Brogi D; Brescia Morra V; Guidi L; Pozzilli C; Comi G; Lugaresi A; Turrini R; Raimondi D; Uccelli A; Mancardi GL
    Neurol Sci; 2017 Jan; 38(1):53-59. PubMed ID: 27757552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Outcomes in Fingolimod-Treated Patients with Multiple Sclerosis in the Czech Republic: Results from the 12-Month GOLEMS Study.
    Tichá V; Kodým R; Počíková Z; Kadlecová P
    Clin Drug Investig; 2017 Feb; 37(2):175-186. PubMed ID: 27785735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cryptococcal meningitis in a multiple sclerosis patient treated with Fingolimod: a case report and review of imaging findings.
    Chong I; Wang KY; Lincoln CM
    Clin Imaging; 2019; 54():53-56. PubMed ID: 30544079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fingolimod for relapsing multiple sclerosis: an update.
    Horga A; Castilló J; Montalban X
    Expert Opin Pharmacother; 2010 May; 11(7):1183-96. PubMed ID: 20367536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of fingolimod in clinical practice.
    Thomas K; Ziemssen T
    Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S60-4. PubMed ID: 24321158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
    Singer B; Ross AP; Tobias K
    Int J Clin Pract; 2011 Aug; 65(8):887-95. PubMed ID: 21679286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycosis fungoides - A cutaneous lymphoproliferative disorder in a patient treated with fingolimod for multiple sclerosis.
    Nitsan Z; Kucuk N; Appel S; Tichmanovich N; Osherov M; Milo R
    J Clin Neurosci; 2018 Feb; 48():102-103. PubMed ID: 29108666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
    Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod.
    Ziemssen T; Kern R; Cornelissen C
    BMC Neurol; 2016 Aug; 16():129. PubMed ID: 27502119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.